论文部分内容阅读
目的观察依达拉奉联合巴曲酶治疗进展性脑梗死的疗效。方法选择发病在48h内进展性脑梗死患者80例,随机分为治疗组(40例)和对照组(40例),两组均用巴曲酶治疗,治疗组加用依达拉奉,观察治疗后神经功能改善情况及血浆纤维蛋白原(Fb)含量的变化。结果3周后治疗组有效率85%,高于对照组72.5%(P<0.05),两次治疗后Fb水平较治疗前明显降低(均P<0.01)。结论依达拉奉联合巴曲酶治疗进展性脑梗死安全有效。
Objective To observe the therapeutic effect of edaravone and batroxobin on patients with progressive cerebral infarction. Methods Eighty patients with progressive cerebral infarction within 48h were randomly divided into treatment group (40 cases) and control group (40 cases). Both groups were treated with batroxobin and edaravone was given to the treatment group Changes of neurological function and plasma fibrinogen (Fb) content after treatment. Results After 3 weeks, the effective rate of the treatment group was 85%, which was higher than that of the control group (72.5%, P <0.05). The levels of Fb in the two groups were significantly lower than those before treatment (all P <0.01). Conclusion Edaravone and batroxobin are safe and effective in treating progressive cerebral infarction.